Richard P Allen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/59088/publications.pdf

Version: 2024-02-01

213 papers	24,565 citations	7096 78 h-index	7160 153 g-index
215 all docs	215 docs citations	215 times ranked	7068 citing authors

#	Article	IF	Citations
1	A Quantitative Systems Pharmacology Perspective on the Importance of Parameter Identifiability. Bulletin of Mathematical Biology, 2022, 84, 39.	1.9	19
2	Innovative Randomized Phase I Study and Dosing Regimen Selection to Accelerate and Inform Pivotal COVIDâ€19 Trial of Nirmatrelvir. Clinical Pharmacology and Therapeutics, 2022, 112, 101-111.	4.7	76
3	Pilot study: can machine learning analyses of movement discriminate between leg movements in sleep (LMS) with vs. without cortical arousals?. Sleep and Breathing, 2021, 25, 373-379.	1.7	4
4	A Prototype QSP Model of the Immune Response to SARSâ€CoVâ€2 for Community Development. CPT: Pharmacometrics and Systems Pharmacology, 2021, 10, 18-29.	2.5	16
5	Developing a biomarker for restless leg syndrome using genome wide DNA methylation data. Sleep Medicine, 2021, 78, 120-127.	1.6	4
6	Pharmacologic inhibition of ketohexokinase prevents fructose-induced metabolic dysfunction. Molecular Metabolism, 2021, 48, 101196.	6.5	42
7	Akathisia and Restless Legs Syndrome. Sleep Medicine Clinics, 2021, 16, 249-267.	2.6	9
8	Nighttime Agitation in Persons with Dementia as a Manifestation of Restless Legs Syndrome. Journal of the American Medical Directors Association, 2021, 22, 1410-1414.	2.5	8
9	We need to do better: A systematic review and meta-analysis of diagnostic test accuracy of restless legs syndrome screening instruments. Sleep Medicine Reviews, 2021, 58, 101461.	8.5	22
10	Randomized, placebo-controlled trial of ferric carboxymaltose in restless legs syndrome patients with iron deficiency anemia. Sleep Medicine, 2021, 84, 179-186.	1.6	7
11	Clinical efficacy and safety of intravenous ferric carboxymaltose treatment of pediatric restless legs syndrome and periodic limb movement disorder. Sleep Medicine, 2021, 87, 114-118.	1.6	16
12	Consensus Guidelines on Rodent Models of Restless Legs Syndrome. Movement Disorders, 2021, 36, 558-569.	3.9	23
13	The Safety and Efficacy of Pregabalin Add-on Therapy in Restless Legs Syndrome Patients. Frontiers in Neurology, 2021, 12, 786408.	2.4	2
14	Moderate to severe but not mild RLS is associated with greater sleep-related sympathetic autonomic activation than healthy adults without RLS. Sleep Medicine, 2020, 68, 89-95.	1.6	15
15	Resting-state connectivity and the effects of treatment in restless legs syndrome. Sleep Medicine, 2020, 67, 33-38.	1.6	9
16	Consensus diagnostic criteria for a newly defined pediatric sleep disorder: restless sleep disorder (RSD). Sleep Medicine, 2020, 75, 335-340.	1.6	40
17	Patient characteristics predicting responses to intravenous ferric carboxymaltose treatment of restless legs syndrome. Sleep Medicine, 2020, 75, 81-87.	1.6	5
18	A novel sleep stage scoring system: Combining expertâ€based features with the generalized linear model. Journal of Sleep Research, 2020, 29, e12991.	3.2	4

#	Article	IF	Citations
19	Iron-deficiency and dopaminergic treatment effects on RLS-Like behaviors of an animal model with the brain iron deficiency pattern of the restless legs syndrome. Sleep Medicine, 2020, 71, 141-148.	1.6	15
20	Developing a behavioral model of Restless Legs Syndrome utilizing mice with natural variances in ventral midbrain iron. Sleep Medicine, 2020, 71, 135-140.	1.6	4
21	Evidence for communication of peripheral iron status to cerebrospinal fluid: clinical implications for therapeutic strategy. Fluids and Barriers of the CNS, 2020, 17, 28.	5.0	6
22	New Insights into the Neurobiology of Restless Legs Syndrome. Neuroscientist, 2019, 25, 113-125.	3.5	85
23	0656 Validation of the Self-administered Version of the International Restless Legs Syndrome Study Group Severity Rating Scale - the sIRLS. Sleep, 2019, 42, A261-A262.	1.1	1
24	Development and Validation of RLS Diagnostic Questionnaire for Indian Population. Sleep and Vigilance, 2019, 3, 39-48.	0.8	2
25	Extracellular vesicles reveal abnormalities in neuronal iron metabolism in restless legs syndrome. Sleep, 2019, 42, .	1.1	13
26	Reply to: A note on rotigotine for restless legs syndrome after renal transplantation. Movement Disorders, 2019, 34, 152-153.	3.9	0
27	Validation of the self-administered version of the international Restless Legs Syndrome study group severity rating scale â€“ The sIRLS. Sleep Medicine, 2019, 54, 94-100.	1.6	34
28	Reply to: Safety of dopamine agonists for treating restless legs syndrome. Movement Disorders, 2019, 34, 150-151.	3.9	1
29	Evidence-based and consensus clinical practice guidelines for the iron treatment of restless legs syndrome/Willis-Ekbom disease in adults and children: an IRLSSG task force report. Sleep Medicine, 2018, 41, 27-44.	1.6	228
30	Restless legs syndrome is associated with major comorbidities in a population of Danish blood donors. Sleep Medicine, 2018, 45, 124-131.	1.6	23
31	Association Between Non-Iron-Deficient Anemia and Insomnia Symptoms in Community-Dwelling Older Adults: The Baltimore Longitudinal Study of Aging. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2018, 73, 380-385.	3.6	9
32	Diurnal variation of default mode network in patients with restless legs syndrome. Sleep Medicine, 2018, 41, 1-8.	1.6	29
33	Efficacy of ferric carboxymaltose (FCM) 500Âmg dose for the treatment of Restless Legs Syndrome. Sleep Medicine, 2018, 42, 7-12.	1.6	16
34	Comparison of Subjective Sleep Quality of Long-Term Residents at Low and High Altitudes: SARAHA Study. Journal of Clinical Sleep Medicine, 2018, 14, 15-21.	2.6	14
35	Comorbidities, treatment, and pathophysiology in restless legs syndrome. Lancet Neurology, The, 2018, 17, 994-1005.	10.2	166
36	Treatment of restless legs syndrome: Evidenceâ€based review and implications for clinical practice (Revised 2017)^{Â§}. Movement Disorders, 2018, 33, 1077-1091.	3.9	136

#	Article	IF	Citations
37	Assessment of change in restless legs syndrome symptoms during the acute drug-withdrawal period. Sleep Medicine, 2018, 52, 80-87.	1.6	4
38	Connecting clinical aspects to corticomotor excitability in restless legs syndrome: a TMS study. Sleep Medicine, 2018, 49, 105-112.	1.6	14
39	Evaluation and Management of RLSÂand PLMD. , 2017, , 759-786.		0
40	Introduction: Towards a better understanding of the science of RLS/WED. Sleep Medicine, 2017, 31, 1-2.	1.6	14
41	High prevalence of restless legs syndrome/Willis Ekbom Disease (RLS/WED) among people living at high altitude in the Indian Himalaya. Sleep Medicine, 2017, 35, 7-11.	1.6	36
42	Intervening Leg Movements Disrupt PLMS Sequences. Sleep, 2017, 40, .	1.1	3
43	Identification of novel risk loci for restless legs syndrome in genome-wide association studies in individuals of European ancestry: a meta-analysis. Lancet Neurology, The, 2017, 16, 898-907.	10.2	191
44	Prevalence of restless legs syndrome and associated factors in an otherwise healthy population: results from the Danish Blood Donor Study. Sleep Medicine, 2017, 36, 55-61.	1.6	51
45	Animal models of RLS phenotypes. Sleep Medicine, 2017, 31, 23-28.	1.6	30
46	Iron and restless legs syndrome: treatment, genetics and pathophysiology. Sleep Medicine, 2017, 31, 61-70.	1.6	90
47	Targeting hypersensitive corticostriatal terminals in restless legs syndrome. Annals of Neurology, 2017, 82, 951-960.	5.3	52
48	Pivotal Role of Adenosine Neurotransmission in Restless Legs Syndrome. Frontiers in Neuroscience, 2017, 11, 722.	2.8	64
49	Motor Control and Dyscontrol in Sleep. , 2017, , 713-757.		1
50	Restless Legs Syndrome and Periodic Limb Movements During Sleep. , 2017, , 923-934.e6.		5
51	Depth and Distribution of Symptoms in Restless Legs Syndrome/ Willis-Ekbom Disease. Journal of Clinical Sleep Medicine, 2016, 12, 1669-1680.	2.6	9
52	Inter-movement interval as a primary stable measure of periodic limb movements of sleep. Sleep Medicine, 2016, 17, 138-143.	1.6	8
53	Adenosine receptors as markers of brain iron deficiency: Implications for Restless Legs Syndrome. Neuropharmacology, 2016, 111, 160-168.	4.1	45
54	Clinical efficacy of ferric carboxymaltose treatment in patients with restless legs syndrome. Sleep Medicine, 2016, 25, 16-23.	1.6	46

#	Article	IF	Citations
55	Defining morphology of periodic leg movements in sleep: an evidence-based definition of a minimum window of sustained activity. Sleep and Breathing, 2016, 20, 1293-1299.	1.7	5
56	Default mode network disturbances in restless legs syndrome/Willisâ€“Ekbom disease. Sleep Medicine, 2016, 23, 6-11.	1.6	27
57	Practice guideline summary: Treatment of restless legs syndrome in adults. Neurology, 2016, 87, 2585-2593.	1.1	182
58	Brain iron deficiency in idiopathic restless legs syndrome measured by quantitative magnetic susceptibility at 7 tesla. Sleep Medicine, 2016, 22, 75-82.	1.6	70
59	Guidelines for the first-line treatment of restless legs syndrome/Willisâ€“Ekbom disease, prevention and treatment of dopaminergic augmentation: a combined task force of the IRLSSG, EURLSSG, and the RLS-foundation. Sleep Medicine, 2016, 21, 1-11.	1.6	242
60	Restless legs syndrome associated with major diseases. Neurology, 2016, 86, 1336-1343.	1.1	276
61	Effects of rotigotine on daytime symptoms in patients with primary restless legs syndrome: a randomized, placebo-controlled study. Current Medical Research and Opinion, 2016, 32, 77-85.	1.9	12
62	Response to the letter â€œCharacterization of the painful restless legs syndromeâ€• Sleep Medicine, 2015, 16, 1448.	1.6	1
63	Diagnostic Accuracy of Behavioral, Activity, Ferritin, and Clinical Indicators of Restless Legs Syndrome. Sleep, 2015, 38, 371-380.	1.1	12
64	A comparison of MRI tissue relaxometry and ROI methods used to determine regional brain iron concentrations in restless legs syndrome. Medical Devices: Evidence and Research, 2015, 8, 341.	0.8	9
65	MATPLM1, A MATLAB script for scoring of periodic limb movements: preliminary validation with visual scoring. Sleep Medicine, 2015, 16, 1541-1549.	1.6	18
66	Co-registration of magnetic resonance spectroscopy and transcranial magnetic stimulation. Journal of Neuroscience Methods, 2015, 242, 52-57.	2.5	9
67	Response to â€œCharacterization of the painful restless legs syndromeâ€• Sleep Medicine, 2015, 16, 898.	1.6	0
68	Restless Leg Syndrome/Willis-Ekbom Disease Pathophysiology. Sleep Medicine Clinics, 2015, 10, 207-214.	2.6	126
69	Prevalence and clinical characteristics of patients with restless legs syndrome with painful symptoms. Sleep Medicine, 2015, 16, 775-778.	1.6	33
70	Augmentation of restless leg syndrome (Willis-Ekbom disease) during long-term dopaminergic treatment. Postgraduate Medicine, 2015, 127, 716-725.	2.0	26
71	Gray matter alteration in patients with restless legs syndrome: a voxel-based morphometry study. Clinical Imaging, 2015, 39, 20-25.	1.5	36
72	History of Restless Legs Syndrome, Recently Named Willisâ€“Ekbom Disease. , 2015, , 249-254.		0

#	Article	IF	Citations
73	Association Between Anemia Subtypes and Insomnia Symptoms in Communityâ€Dwelling Older Adults. FASEB Journal, 2015, 29, 392.7.	0.5	0
74	Altered white matter integrity in primary restless legs syndrome patients: diffusion tensor imaging study. Neurological Research, 2014, 36, 769-774.	1.3	28
75	Response to intravenous iron in patients with iron deficiency anemia (IDA) and restless leg syndrome (Willisâ€“Ekbom disease). Sleep Medicine, 2014, 15, 1473-1476.	1.6	55
76	Valid measures of periodic leg movements (PLMs) during a suggested immobilization test using the PAM-RL leg activity monitors require adjusting detection parameters for noise and signal in each recording. Sleep Medicine, 2014, 15, 132-137.	1.6	8
77	Comparison of Pregabalin with Pramipexole for Restless Legs Syndrome. New England Journal of Medicine, 2014, 370, 621-631.	27.0	189
78	Functional connectivity alternation of the thalamus in restless legs syndrome patients during the asymptomatic period: a resting-state connectivity study using functional magnetic resonance imaging. Sleep Medicine, 2014, 15, 289-294.	1.6	63
79	Low brain iron effects and reversibility on striatal dopamine dynamics. Experimental Neurology, 2014, 261, 462-468.	4.1	52
80	Altered Brain iron homeostasis and dopaminergic function in Restless Legs Syndrome (Willisâ€“Ekbom) Tj ETQq0 0 0 rgBT /Overlock 10	1.6	251
81	Restless legs syndrome/Willis Ekbom disease: Evaluation and treatment. International Review of Psychiatry, 2014, 26, 248-262.	2.8	25
82	Restless legs syndrome/Willisâ€“Ekbom disease diagnostic criteria: updated International Restless Legs Syndrome Study Group (IRLSSG) consensus criteria â€“ history, rationale, description, and significance. Sleep Medicine, 2014, 15, 860-873.	1.6	1,123
83	Review of Quality of Life Instruments for the Restless Legs Syndrome/Willis-Ekbom Disease (RLS/WED): Critique and Recommendations. Journal of Clinical Sleep Medicine, 2014, 10, 1351-1357.	2.6	25
84	Review of Severity Rating Scales for Restless Legs Syndrome: Critique and Recommendations. Movement Disorders Clinical Practice, 2014, 1, 317-324.	1.5	32
85	Pregabalin Versus Pramipexole: Effects on Sleep Disturbance in Restless Legs Syndrome. Sleep, 2014, 37, 635-643.	1.1	68
86	Increased Use-Dependent Plasticity in Chronic Insomnia. Sleep, 2014, 37, 535-544.	1.1	16
87	Review of Diagnostic Instruments for the Restless Legs Syndrome/Willis-Ekbom Disease (RLS/WED): Critique and Recommendations. Journal of Clinical Sleep Medicine, 2014, 10, 1343-1349.	2.6	47
88	Proteomic analysis of the cerebrospinal fluid of patients with restless legs syndrome/Willis-Ekbom disease. Fluids and Barriers of the CNS, 2013, 10, 20.	5.0	32
89	The long-term treatment of restless legs syndrome/Willisâ€“Ekbom disease: evidence-based guidelines and clinical consensus best practice guidance: a report from the International Restless Legs Syndrome Study Group. Sleep Medicine, 2013, 14, 675-684.	1.6	260
90	Prevalence and clinical characteristics of restless legs syndrome in diabetic peripheral neuropathy: comparison with chronic osteoarthritis. Sleep Medicine, 2013, 14, 1387-1392.	1.6	25

#	Article	IF	Citations
91	Prolonged release oxycodoneâ€“naloxone for treatment of severe restless legs syndrome after failure of previous treatment: a double-blind, randomised, placebo-controlled trial with an open-label extension. Lancet Neurology, The, 2013, 12, 1141-1150.	10.2	188
92	Relation of the International Restless Legs Syndrome Study Group rating scale with the Clinical Global Impression severity scale, the restless legs syndrome 6-item questionnaire, and the restless legs syndrome-quality of life questionnaire. Sleep Medicine, 2013, 14, 1375-1380.	1.6	21
93	Lower molecular weight intravenous iron dextran for restless legs syndrome. Sleep Medicine, 2013, 14, 274-277.	1.6	54
94	Minimal clinically significant change for the International Restless Legs Syndrome Study Group rating scale in clinical trials is a score of 3. Sleep Medicine, 2013, 14, 1229.	1.6	30
95	The prevalence and impact of restless legs syndrome on patients with iron deficiency anemia. American Journal of Hematology, 2013, 88, 261-264.	4.1	189
96	Thalamic glutamate/glutamine in restless legs syndrome. Neurology, 2013, 80, 2028-2034.	1.1	156
97	Increased Synaptic Dopamine in the Putamen in Restless Legs Syndrome. Sleep, 2013, 36, 51-57.	1.1	93
98	Role of Striatal A2A Receptor Subpopulations in Neurological Disorders. , 2013, , 179-197.		1
99	Systems genetic analysis of multivariate response to iron deficiency in mice. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2012, 302, R1282-R1296.	1.8	24
100	Assessing health-related quality of life in patients with restless legs syndrome in Korea: Comparison with other chronic medical diseases. Sleep Medicine, 2012, 13, 1158-1163.	1.6	27
101	When gender matters: Restless legs syndrome. Report of the â€œRLS and womanâ€•workshop endorsed by the European RLS Study Group. Sleep Medicine Reviews, 2012, 16, 297-307.	8.5	115
102	Restless legs syndrome symptomatology, attitudes and beliefs among treated and untreated individuals. Sleep Medicine, 2012, 13, 1226-1231.	1.6	5
103	Restless Legs Syndrome (Willis-Ekbom Disease) and Periodic Limb Movements. , 2012, , .		4
104	Systems genetic analysis of the effects of iron deficiency in mouse brain. Neurogenetics, 2012, 13, 147-157.	1.4	36
105	Systematic evaluation of augmentation during treatment with ropinirole in restless legs syndrome (Willisâ€Ekbom Disease): Results from a prospective, multicenter study over 66 weeks. Movement Disorders, 2012, 27, 277-283.	3.9	61
106	Development and validation of a Subjective Post Sleep Diary (SPSD) to assess sleep status in subjects with Restless Legs Syndrome. Sleep Medicine, 2011, 12, 704-710.	1.6	9
107	Postmortem and imaging based analyses reveal CNS decreased myelination in restless legs syndrome. Sleep Medicine, 2011, 12, 614-619.	1.6	72
108	A 10-year, longitudinal assessment of dopamine agonists and methadone in the treatment of restless legs syndrome. Sleep Medicine, 2011, 12, 440-444.	1.6	159

#	Article	IF	Citations
109	Restless legs syndrome (RLS) augmentation associated with dopamine agonist and levodopa usage in a community sample. Sleep Medicine, 2011, 12, 431-439.	1.6	123
110	Clinical efficacy and safety of IV ferric carboxymaltose (FCM) treatment of RLS: A multi-centred, placebo-controlled preliminary clinical trial. Sleep Medicine, 2011, 12, 906-913.	1.6	126
111	Restless Legs Syndrome and Periodic Limb Movements during Sleep. , 2011, , 1026-1037.		23
112	The Dopamine Transporter is Decreased in the Striatum of Subjects with Restless Legs Syndrome. Sleep, 2011, 34, 341-347.	1.1	126
113	Prevalence and disease burden of primary restless legs syndrome: Results of a general population survey in the United States. Movement Disorders, 2011, 26, 114-120.	3.9	187
114	Profile of altered brain iron acquisition in restless legs syndrome. Brain, 2011, 134, 959-968.	7.6	203
115	Restless legs syndrome and periodic leg movements in sleep. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2011, 99, 913-948.	1.8	21
116	Genome-Wide Association Study Identifies Novel Restless Legs Syndrome Susceptibility Loci on 2p14 and 16q12.1. PLoS Genetics, 2011, 7, e1002171.	3.5	163
117	Funciones y disfunciones motoras del sueÃ±o. , 2011, , 397-435.		0
118	Progressive development of augmentation during long-term treatment with levodopa in restless legs syndrome: results of a prospective multi-center study. Journal of Neurology, 2010, 257, 230-237.	3.6	88
119	Rotigotine improves restless legs syndrome: A 6â€month randomized, doubleâ€blind, placeboâ€controlled trial in the United States. Movement Disorders, 2010, 25, 1675-1683.	3.9	102
120	Update in restless legs syndrome. Current Opinion in Neurology, 2010, 23, 401-406.	3.6	70
121	Physician-diagnosed restless legs syndrome in a large sample of primary medical care patients in western Europe: Prevalence and characteristics. Sleep Medicine, 2010, 11, 31-37.	1.6	177
122	Pregnancy accounts for most of the gender difference in prevalence of familial RLS. Sleep Medicine, 2010, 11, 310-313.	1.6	90
123	A randomized, double-blind, 6-week, dose-ranging study of pregabalin in patients with restless legs syndrome. Sleep Medicine, 2010, 11, 512-519.	1.6	91
124	Development of the Pediatric Restless Legs Syndrome Severity Scale (P-RLS-SS)Â©: A patient-reported outcome measure of pediatric RLS symptoms and impact. Sleep Medicine, 2010, 11, 897-906.	1.6	48
125	Up-regulation of striatal adenosine A2A receptors with iron deficiency in rats. Experimental Neurology, 2010, 224, 292-298.	4.1	27
126	Motor Functions and Dysfunctions of Sleep. , 2009, , 397-435.		18

#	Article	IF	Citations
127	Altered dopaminergic profile in the putamen and substantia nigra in restless leg syndrome. Brain, 2009, 132, 2403-2412.	7.6	299
128	MEIS1 intronic risk haplotype associated with restless legs syndrome affects its mRNA and protein expression levels. Human Molecular Genetics, 2009, 18, 1065-1074.	2.9	85
129	Abnormally increased CSF 3-Ortho-methyldopa (3-OMD) in untreated restless legs syndrome (RLS) patients indicates more severe disease and possibly abnormally increased dopamine synthesis. Sleep Medicine, 2009, 10, 123-128.	1.6	85
130	Evaluating daytime alertness in individuals with Restless Legs Syndrome (RLS) compared to sleep restricted controls. Sleep Medicine, 2009, 10, 134-138.	1.6	42
131	A randomized, double-blind, placebo-controlled trial of intravenous iron sucrose in restless legs syndrome. Sleep Medicine, 2009, 10, 206-211.	1.6	114
132	Psychometric evaluation and tests of validity of the Medical Outcomes Study 12-item Sleep Scale (MOS) Tj ETQq0 0 0 rgBT /Overlock 10	1.6	97
133	RLS and blood donation. Sleep Medicine, 2009, 10, 844-849.	1.6	24
134	The four diagnostic criteria for Restless Legs Syndrome are unable to exclude confounding conditions (â€œmimicsâ€). Sleep Medicine, 2009, 10, 976-981.	1.6	246
135	Validation of the self-completed Cambridge-Hopkins questionnaire (CH-RLSq) for ascertainment of restless legs syndrome (RLS) in a population survey. Sleep Medicine, 2009, 10, 1097-1100.	1.6	181
136	The dopaminergic neurons of the A11 system in RLS autopsy brains appear normal. Sleep Medicine, 2009, 10, 1155-1157.	1.6	75
137	Mitochondrial Ferritin in the Substantia Nigra in Restless Legs Syndrome. Journal of Neuropathology and Experimental Neurology, 2009, 68, 1193-1199.	1.7	68
138	Diagnosis of Restless Legs Syndrome. , 2009, , 99-110.		4
139	Treatment of restless legs syndrome: An evidenceâ€based review and implications for clinical practice. Movement Disorders, 2008, 23, 2267-2302.	3.9	242
140	Validation of the Hopkins telephone diagnostic interview for restless legs syndrome. Sleep Medicine, 2008, 9, 283-289.	1.6	100
141	A further evaluation of the cognitive deficits associated with restless legs syndrome (RLS). Sleep Medicine, 2008, 9, 500-505.	1.6	65
142	Clinical efficacy of ropinirole for restless legs syndrome is not affected by age at symptom onset. Sleep Medicine, 2008, 9, 899-902.	1.6	16
143	Restless Legs Syndrome is Associated with DSM-IV Major Depressive Disorder and Panic Disorder in the Community. Journal of Neuropsychiatry and Clinical Neurosciences, 2008, 20, 101-105.	1.8	154
144	The Restless Legs Syndrome. , 2008, , 445-467.		0

#	Article	IF	Citations
145	Epidemiology of Restless Legs Syndrome in Korean Adults. Sleep, 2008, 31, 219-223.	1.1	119
146	Altered Iron Metabolism in Lymphocytes from Subjects with Restless Legs Syndrome. Sleep, 2008, 31, 847-852.	1.1	35
147	Altered expression of ironâ€management proteins in the brain microvasculature of Restless Legs Syndrome. FASEB Journal, 2008, 22, 1191.5.	0.5	0
148	Restless Legs Syndrome: Prevalence and Impact in Children and Adolescentsâ€"The Peds REST Study. Pediatrics, 2007, 120, 253-266.	2.1	377
149	Predictors of health-related quality of life in sufferers with restless legs syndrome: A multi-national study. Sleep Medicine, 2007, 8, 73-83.	1.6	50
150	Diagnostic Standards for Dopaminergic Augmentation of Restless Legs Syndrome: Report from a World Association of Sleep Medicine â€“ International Restless Legs Syndrome Study Group Consensus Conference at the Max Planck Institute. Sleep Medicine, 2007, 8, 520-530.	1.6	264
151	Validation of the Augmentation Severity Rating Scale (ASRS): A multicentric, prospective study with levodopa on restless legs syndrome. Sleep Medicine, 2007, 8, 455-463.	1.6	97
152	Improving RLS diagnosis and severity assessment: Polysomnography, actigraphy and RLS-sleep log. Sleep Medicine, 2007, 8, S13-S18.	1.6	34
153	Controversies and Challenges in Defining the Etiology and Pathophysiology of Restless Legs Syndrome. American Journal of Medicine, 2007, 120, S13-S21.	1.5	112
154	Assessment of restless legs syndromeâ€"Methodological approaches for use in practice and clinical trials. Movement Disorders, 2007, 22, S485-S494.	3.9	40
155	The role of iron in restless legs syndrome. Movement Disorders, 2007, 22, S440-S448.	3.9	243
156	Augmentation as a treatment complication of restless legs syndrome: Concept and management. Movement Disorders, 2007, 22, S476-S484.	3.9	81
157	Is ferroportinâ€“hepcidin signaling altered in restless legs syndrome?. Journal of the Neurological Sciences, 2006, 247, 173-179.	0.6	73
158	Circadian changes in CSF dopaminergic measures in restless legs syndrome. Sleep Medicine, 2006, 7, 263-268.	1.6	85
159	MRI-determined regional brain iron concentrations in early- and late-onset restless legs syndrome. Sleep Medicine, 2006, 7, 458-461.	1.6	219
160	The reliability, validity and responsiveness of the International Restless Legs Syndrome Study Group rating scale and subscales in a clinical-trial setting. Sleep Medicine, 2006, 7, 340-349.	1.6	95
161	The official World Association of Sleep Medicine (WASM) standards for recording and scoring periodic leg movements in sleep (PLMS) and wakefulness (PLMW) developed in collaboration with a task force from the International Restless Legs Syndrome Study Group (IRLSSG). Sleep Medicine, 2006, 7, 175-183.	1.6	444
162	Undiagnosed individuals with first-degree relatives with restless legs syndrome have increased periodic limb movements. Sleep Medicine, 2006, 7, 480-485.	1.6	23

#	Article	IF	Citations
163	Restless legs syndrome augmentation associated with tramadol. Sleep Medicine, 2006, 7, 592-593.	1.6	92
164	When, if ever, can we use REM-onset naps on the MSLT for the diagnosis of narcolepsy?. Sleep Medicine, 2006, 7, 657-659.	1.6	4
165	The effects of dietary iron deprivation on murine circadian sleep architecture. Sleep Medicine, 2006, 7, 634-640.	1.6	46
166	Ferritin subunits in CSF are decreased in restless legs syndrome. Translational Research, 2006, 147, 67-73.	2.3	70
167	Segregation Analysis of Restless Legs Syndrome: Possible Evidence for a Major Gene in a Family Study Using Blinded Diagnoses. Human Heredity, 2006, 62, 157-164.	0.8	35
168	Validation of the Restless Legs Syndrome Quality of Life Questionnaire. Value in Health, 2005, 8, 157-167.	0.3	105
169	Investigation into the correlation between sensation and leg movement in restless legs syndrome. Movement Disorders, 2005, 20, 1097-1103.	3.9	17
170	Ferritin Levels in the Cerebrospinal Fluid and Restless Legs Syndrome: Effects of Different Clinical Phenotypes. Sleep, 2005, 28, 1069-1075.	1.1	104
171	Restless Legs Syndrome Prevalence and Impact. Archives of Internal Medicine, 2005, 165, 1286.	3.8	1,046
172	An item response analysis of the international restless legs syndrome study group rating scale for restless legs syndrome. Sleep Medicine, 2005, 6, 131-139.	1.6	37
173	Repeated IV doses of iron provides effective supplemental treatment of restless legs syndrome. Sleep Medicine, 2005, 6, 301-305.	1.6	101
174	Effects of rest-duration, time-of-day and their interaction on periodic leg movements while awake in restless legs syndrome. Sleep Medicine, 2005, 6, 429-434.	1.6	25
175	The reliability, validity and responsiveness of the Restless Legs Syndrome Quality of Life questionnaire (RLSQoL) in a trial population. Health and Quality of Life Outcomes, 2005, 3, 79.	2.4	66
176	An Update on the Dopaminergic Treatment of Restless Legs Syndrome and Periodic Limb Movement Disorder. Sleep, 2004, 27, 560-583.	1.1	283
177	Alcoholics' Attributions Concerning Abstinence and Returning to Drinking. Alcoholism Treatment Quarterly, 2004, 22, 63-79.	0.8	5
178	Thy1 expression in the brain is affected by iron and is decreased in Restless Legs Syndrome. Journal of the Neurological Sciences, 2004, 220, 59-66.	0.6	69
179	An Algorithm for the Management of Restless Legs Syndrome. Mayo Clinic Proceedings, 2004, 79, 916-922.	3.0	287
180	Dopamine and iron in the pathophysiology of restless legs syndrome (RLS). Sleep Medicine, 2004, 5, 385-391.	1.6	366

#	Article	IF	Citations
181	The treatment of restless legs syndrome with intravenous iron dextran. Sleep Medicine, 2004, 5, 231-235.	1.6	190
182	Impact, diagnosis and treatment of restless legs syndrome (RLS) in a primary care population: the REST (RLS epidemiology, symptoms, and treatment) primary care study. Sleep Medicine, 2004, 5, 237-246.	1.6	588
183	Modeling the causal relationships between symptoms associated with restless legs syndrome and the patient-reported impact of RLS. Sleep Medicine, 2004, 5, 485-488.	1.6	81
184	Correlation between rating scales and sleep laboratory measurements in restless legs syndrome. Sleep Medicine, 2004, 5, 561-565.	1.6	79
185	Evaluating the quality of life of patients with restless legs syndrome. Clinical Therapeutics, 2004, 26, 925-935.	2.5	263
186	Ropinirole Decreases Periodic Leg Movements and Improves Sleep Parameters in Patients with Restless Legs Syndrome. Sleep, 2004, 27, 907-914.	1.1	225
187	Take afternoon naps to improve perceptual learning. Sleep Medicine, 2003, 4, 589-590.	1.6	2
188	Factor analysis of the International Restless Legs Syndrome Study Group's scale for restless legs severity. Sleep Medicine, 2003, 4, 133-135.	1.6	112
189	Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome. Sleep Medicine, 2003, 4, 121-132.	1.6	1,488
190	The Johns Hopkins telephone diagnostic interview for the restless legs syndrome: preliminary investigation for validation in a multi-center patient and control population. Sleep Medicine, 2003, 4, 137-141.	1.6	86
191	Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. Sleep Medicine, 2003, 4, 101-119.	1.6	2,868
192	Does a modest loss of sleep affect neurocognitive functioning of children?. Sleep Medicine, 2003, 4, 353-355.	1.6	4
193	Should we aggressively evaluate and treat sleepiness in the elderly?. Sleep Medicine, 2003, 4, 477-478.	1.6	0
194	Alcoholics' Evaluations of Alcoholism Treatment. Alcoholism Treatment Quarterly, 2003, 21, 1-18.	0.8	4
195	Restless Legs Syndrome Symptoms in Primary Care. Archives of Internal Medicine, 2003, 163, 2323.	3.8	192
196	Article reviewed: Mortality associated with sleep duration and insomnia. Sleep Medicine, 2002, 3, 373-375.	1.6	6
197	Validation of the Johns Hopkins restless legs severity scale. Sleep Medicine, 2001, 2, 239-242.	1.6	162
198	Restless legs syndrome (RLS) and periodic leg movements (PLM). , 2001, , 213-228.		1

#	Article	IF	Citations
199	Restless Legs Syndrome. Journal of Clinical Neurophysiology, 2001, 18, 128-147.	1.7	474
200	CSF dopamine, serotonin, and biopterin metabolites in patients with restless legs syndrome. Movement Disorders, 2001, 16, 144-149.	3.9	69
201	Insight into the pathophysiology of restless legs syndrome. Journal of Neuroscience Research, 2000, 62, 623-628.	2.9	209
202	Defining the phenotype of the restless legs syndrome (RLS) using age-of-symptom-onset. Sleep Medicine, 2000, 1, 11-19.	1.6	211
203	Insight into the pathophysiology of restless legs syndrome. Journal of Neuroscience Research, 2000, 62, 623-628.	2.9	1
204	Sleep, Anxiety, and Depression in Abstinent and Drinking Alcoholics. Substance Use and Misuse, 1999, 34, 347-361.	1.4	14
205	Iron and The Restless Legs Syndrome. Sleep, 1998, 21, 381-387.	1.1	324
206	Pergolide and Carbidopa/Levodopa Treatment of the Restless Legs Syndrome and Periodic Leg Movements in Sleep in a Consecutive Series of Patients. Sleep, 1996, 19, 801-810.	1.1	184
207	Augmentation of the Restless Legs Syndrome With Carbidopa/Levodopa. Sleep, 1996, 19, 205-213.	1.1	424
208	Toward a better definition of the restless legs syndrome. Movement Disorders, 1995, 10, 634-642.	3.9	1,004
209	Persistent Effects of (Â±)3,4-Methylenedioxymethamphetamine (MDMA, â€œEcstasyâ€) on Human Sleep. Sleep, 1993, 16, 560-564.	1.1	108
210	Snap-Gauge Compared to a Full Nocturnal Penile Tumescence Study for Evaluation of Patients with Erectile Impotence. Journal of Urology, 1990, 143, 51-54.	0.4	23
211	Locating and Interviewing Alcoholics 8 Years After Discharge from Hospital. Substance Use and Misuse, 1988, 23, 379-386.	0.6	6
212	Efficacy Without Tolerance or Rebound Insomnia for Midazolam and Temazepam After Use for One to Three Months. Journal of Clinical Pharmacology, 1987, 27, 768-775.	2.0	33
213	Socioeconomic factors influencing the rate of nonâ€promotion in elementary schools. Peabody Journal of Education, 1977, 54, 275-281.	1.3	8